EP0828712A1 - Agonistes du recepteur beta-adrenergique - Google Patents

Agonistes du recepteur beta-adrenergique

Info

Publication number
EP0828712A1
EP0828712A1 EP95915993A EP95915993A EP0828712A1 EP 0828712 A1 EP0828712 A1 EP 0828712A1 EP 95915993 A EP95915993 A EP 95915993A EP 95915993 A EP95915993 A EP 95915993A EP 0828712 A1 EP0828712 A1 EP 0828712A1
Authority
EP
European Patent Office
Prior art keywords
compound
alkyl
formula
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95915993A
Other languages
German (de)
English (en)
Inventor
Robert L. Dow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP0828712A1 publication Critical patent/EP0828712A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Definitions

  • the present invention relates to certain compounds of the formula (I) depicted below, which are ⁇ -adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobes ' rty agents.
  • the invention also relates to methods for the compounds use and to pharmaceutical compositions containing them.
  • the compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in edible animals, i.e. ungulate animals and poultry.
  • the compounds of this invention further possess utility in the treatment of intestinal motility disorders, depression, prostate disease, dyslipidemia, and airway inflamatory disorders such as asthma and obstructive lung disease.
  • the disease diabetes mellitus is characterized by metabolic defects in production and utilization of carbohydrates which result in the failure to maintain appropriate blood sugar levels. The result of these defects is elevated blood glucose or hyperglycemia. Research in the treatment of diabetes has centered on attempts to normalize fasting and postprandial blood glucose levels. Current treatments include administration of exogenous insulin, oral administration of drugs and dietary therapies.
  • Type I diabetes or insulin-dependent diabetes
  • Type II diabetes or non-insulin dependent diabetes
  • Type II diabetes often occurs with normal, or even elevated levels of insulin and appears to be the result of the inability of tissues to respond appropriately to insulin.
  • the compounds of the present invention and the pharmaceutically active salts thereof effectively lower blood glucose levels when administered orally to mammals with hyperglycemia or diabetes.
  • the compounds of the present invention also reduce body weight or decrease weight gain when administered to mammals.
  • the ability of these compounds to affect weight gain is due to activation of ⁇ -adrenergic receptors which stimulate the metabolism of adipose tissue.
  • ⁇ -Adrenergic receptors have been categorized into ⁇ 1( ⁇ 2 and ⁇ 3 -subtypes.
  • Agonists of ⁇ -receptors promote the activation of adenyl cyclase.
  • Activation of ⁇ ,- receptors invokes increases in heart rate while activation of ⁇ 2 -receptors induces relaxation of skeletal muscle tissue which produces a drop in blood pressure and the onset of smooth muscle tremors.
  • ⁇ 3 -receptors Activation of ⁇ 3 -receptors is known to stimulate lipolysis (the breakdown of adipose tissue trigiycerides to glyceroi and free fatty acids) and metabolic rate (energy expenditure), and thereby promote the loss of fat mass.
  • Compounds that stimulate ⁇ -receptors are therefore useful as anti-obesity agents, and can also be used to increase the content of lean meat in edible animals.
  • compounds which are ⁇ 3 -receptor agonists have hypoglycemic or anti-diabetic activity, but the mechanism of this effect is unknown. Until recently ⁇ 3 -adrenergic receptors were thought to be found predominantly in adipose tissue.
  • ⁇ 3 -receptors are now known to be located in such diverse tissues as the intestine U. Clin. Invest.. 91., 344 (1993)) and the brain (Eur. J. Pharm.. 219.193 (1992)). Stimulation of the ⁇ 3 -receptor has been demonstrated to cause relaxation of smooth muscle in colon, trachea and bronchi. Life Sciences.44(19), 1411 (1989); Br. J. Pharm.. 112. 55 (1994); Br. J. Pharmacol.. 110. 1311 (1993). For example, stimulation of ⁇ 3 -receptors has been found to induce relaxation of histamine-contracted guinea pig ileum, J.Pharm.Exp.Ther.. 260. 1 , 192 (1992).
  • the ⁇ 3 -receptor is also expressed in human prostate. Because stimulation of the ⁇ 3 -receptor causes relaxation of smooth muscles that have been shown to express the ⁇ 3 -receptor (e.g. intestine), one skilled in the art would predict relaxation of prostate smooth muscle. Therefore ⁇ 3 -agonists will be useful for the treatment or prevention of prostate disease.
  • European Patent publication 516,349, published December 2, 1992, refers to certain 2-hydroxyphenethyl amines which possess antiobesity, hypoglycemic and related utilities.
  • U.S. Patent 4,358,455 is concerned with certain heterocyclic compounds of the formula Het-CHOH-CH 2 -NH-aralkyl, useful for treating glaucoma and cardiovascular disorders.
  • U. S. Patent 5,030,640 concerns certain ⁇ -heterocyclic ethanol amino alkyl indoles, useful as growth promoters, bronchodilators, antidepressants and antiobesity agents.
  • R 1 , R 2 , R 4 and R 5 are independently hydrogen or (C 1 -C ⁇ )alkyl
  • R 3 , R 6 and R 7 are independently hydrogen, halogen, (C j -C ⁇ alkyl, nitro, cyano, trifluoromethyl, SO 2 R 8 , SO 2 NR 9 R 10 , NR 9 R 10 , COR 11 , CO 2 R 9 , (C ⁇ C ⁇ alkoxy, NR 9 SO 2 R 8 , NR 9 COR 11 , NR 9 CO 2 R 9 or OR 9 ;
  • R 8 is independently (C 1 -C 6 )alkyl or (C ⁇ C ⁇ alkoxyfC ⁇ C ⁇ alkyl; R 9 and R 10 are independently hydrogen, (C ⁇ CeJalkyl, (C 3 -C 8 )cycloalkyl, or (C
  • R 11 is independently hydrogen, (C ⁇ C ⁇ alkyl, NR 9 R 10 , (C 3 -C ⁇ )cycloalkyl, or (C r C 6 )alkoxy(C 1 -C 6 )alkyl wherein R 9 and R 10 are as defined above;
  • R 12 is independently (C ⁇ C ⁇ aikyi, (C 3 -C 8 )cycloalkyl, or ( ⁇ -C ⁇ Jalkoxy (C r C 6 )alkyl;
  • W is N, CH, or when R 3 is bonded to W, CR 3 wherein R 3 can be any of the values listed above for R 3 in addition to H;
  • X and Y are independently a direct link (i.e. a covalent bond), oxygen, sulfur, or NR 1 wherein R 1 is as defined above;
  • Z is (CH 2 ) n CO 2 R 12 or (CH 2 ) n -O-(CH 2 ) m CO 2 R 12 wherein R 12 is as defined above, m is 1 to 6; n is 0 to 6, provided that if Y is O or S, n is not 0; pharmaceutically acceptable prodrugs of said compounds; and pharmaceutically acceptable salts of said compounds and said prodrugs.
  • Compounds according to the invention are ⁇ -adrenergic receptor agonists.
  • a preferred subgroup of compounds includes those compounds of formula I wherein X is oxygen.
  • Another preferred subgroup includes those compounds of formula I wherein X is oxygen and W is CH.
  • Another preferred subgroup includes those compounds of formula I wherein X is oxygen, W is CH, and each of R 1 , R 2 , R 3 , R 4 R 5 , R 6 and R 7 is H.
  • Another preferred subgroup includes those compounds of formula I wherein X is oxygen, W is CH, each of R 1 , R 2 , R 3 , R 4 R 5 , R 6 and R 7 is H, and Y is oxygen or a direct link.
  • Preferred compounds include the following:
  • the present invention also relates to a therapeutic composition, useful for treating a condition, disease, or disorder in a mammal, including any of the conditions, diseases and/or disorders disclosed herein, comprising an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating such condition, disease, or disorder, and a pharmaceutically acceptable carrier.
  • a therapeutic composition useful for treating a condition, disease, or disorder in a mammal, including any of the conditions, diseases and/or disorders disclosed herein, comprising an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating such condition, disease, or disorder, and a pharmaceutically acceptable carrier.
  • Specific conditions, diseases, and/or disorders which are treatable with such compositions include diabetes, hyperglycemia, obesity, intestinal motility disorders, airway inflammatory disorders, depression, prostate disease, and dyslipidemia.
  • This invention also relates to a method of treating a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating such condition.
  • This invention also relates to a composition, useful for increasing the content of lean meat in edible animals, comprising an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in increasing said content, and a pharmaceutically acceptable carrier.
  • This invention also relates to a method of increasing the content of lean meat in edible animals comprising administering to an edible animal an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in increasing said content.
  • This invention also relates to a method for treating prostate disease in a mammal, preferably a human, comprising administering to a mammal in need of such treatment an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating such disease.
  • the present invention also relates to a method of treating a condition selected from the group consisting of intestinal motility disorders such as irritable bowel syndrome, peptic ulceration, esophagitis, gastritis and duodenitis, (including that induced by J pylori), intestinal ulcerations (including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis) and gastrointestinal ulcerations in a mammal, preferably a human, comprising administering to a mammal in need of such treatment an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating such condition.
  • intestinal motility disorders such as irritable bowel syndrome, peptic ulceration, esophagitis, gastritis and duodenitis, (including that induced by J pylori), intestinal ulcerations (including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis) and gastrointestinal ulcer
  • the present invention also relates to a method for treating depression in a mammal, preferably a human, comprising administering to a mammal in need of such treatment an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating depression.
  • the present invention also relates to a method for treating dyslipidemia in a mammal, preferably a human, comprising administering to a mammal in need of such treatment an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating dyslipidemia.
  • the present invention also relates to a method of treating airway inflamatory disorders, especially asthma, comprising administering to a mammal in need of such treatment an amount of a compound of formula I, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, effective in treating such disorders.
  • This invention includes prodrugs of compounds of formula I having free amino, amido, hydroxy or carboxylic groups.
  • Prodrugs are understood to comprise an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I.
  • the amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, by way of example and not of limitation, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaiin, beta-alanine, gamma-aminobutyric acid, c ' rtrulline homocysteine, homoserine, ornithine and methionine sulfone.
  • Prodrugs are also understood to include carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain.
  • Prodrugs also include compounds in which the secondary amine and its ⁇ -hydroxy when taken together form a group of the formula
  • R 3 , R 4 , R 5 , and X are as defined in formula I, q is 0 to 6, and U and V are independently carbonyl, methylene, SO 2 or SO 3 , wherein methylene is optionally substituted with hydroxy.
  • This invention includes intermediates of the structure:
  • PG is a conventional protecting group
  • R is an alkyl group
  • R 1 , R 4 and R 5 are independently hydrogen or (C C 6 )alkyl;
  • R 3 , R 6 and R 7 are independently hydrogen, halogen, (C ⁇ C ⁇ alkyl, nitro, cyano, trifluoromethyl, SO 2 R 8 , SO 2 NR R 10 , NR 9 R 10 , COR 11 , CO 2 R 9 , ( ⁇ -C ⁇ alkoxy, NR 9 SO 2 R 8 , NR 9 COR 11 , NR 9 CO 2 R 9 or OR 9 ;
  • R 8 is independently (C r C 6 )alkyl or (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl;
  • R 9 and R 10 are independently hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, or (C,- C 6 )alkoxy(C 1 -C 6 )alkyl;
  • R 11 is independently hydrogen, NR 9 R 10 , (C 3 -C 8 )cycloalkyl, or (C,- C 6 )alkoxy(C 1 -C 6 )alkyl wherein R 9 and R 10 are as defined above;
  • R 12 is independently (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, or (C ⁇ C g Jalkoxy ⁇ -C ⁇ Jalkyl; W is N, CH, or when R 3 is bonded to W, CR 3 wherein R 3 can be any of the values listed above for R 3 in addition to H;
  • X and Y are independently a direct link, oxygen, sulfur, or NR 1 wherein R 1 is as defined above;
  • Z is (CH 2 ) n CO 2 R 12 or (CH 2 ) n -O-(CH 2 ) m CO 2 R 12 wherein R 12 is as defined above; m is 1 to 6; n is 0 to 6, provided that if Y is O or S, n is not 0. as further disclosed in detail hereinafter.
  • compounds of formula I because the Y-Z moiety terminates in a carboxylic acid ester moiety, are both active compounds and prodrugs. That is, the esters just mentioned are active compounds. They can also hydrolyze in the body to yield the corresponding (free) carboxylic acids which are also themselves active compounds. Such carboxylic acids have been claimed in Serial No. (Docket PC 8881 JTJ) filed of even date herewith. Such hydrolysis can be desirable since the free acid is selective for the ⁇ 3 -subtype adrenergic receptor. ⁇ 3 -selectivity reduces or avoids undesirable effects of ⁇ ,- and/or ⁇ 2 -agonism, such as increased heart rate, smooth muscle tremoring, and decreased blood pressure.
  • compounds of formula I contain at least one chiral center, and possibly two chiral centers when R 4 and R 5 are different. Accordingly compounds of formula I may exist in, and be isolated in, optically-active and racemic forms. Some compounds may exhibit polymo ⁇ hism.
  • the present invention encompasses any racemic, optically- active, polymorphic or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the treatment of the utilities noted herein, it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the treatment of the said utilities by the standard tests described hereinafter.
  • (R)-stereochemistry is preferred at all chiral centers in the compounds of this invention.
  • alkyl and alkoxy include both straight and branched chain radicals, but it is to be understood that references to individual radicals such as “propyl” or “propoxy” embrace only the straight chain (“normal") radical, branched chain isomers such as “isopropyl” or “isopropoxy” being referred to specifically.
  • halo as used herein, unless otherwise indicated, includes chloro, fluoro, bromo and iodo.
  • treating includes preventative as well as disease rem ' rtative treatment.
  • Particular values of (C 1 -C 6 )alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, and hexyl.
  • (C ⁇ C ⁇ alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentoxy, isopentoxy, and hexoxy.
  • Particularvalues of (C 3 -C 8 )cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyi, and cycloheptyl.
  • More particularvalues of (C 1 -C 6 )alkyl include the values of (C ⁇ C alkyl, including methyl, ethyl, propyl, and isopropyl.
  • (C ⁇ C ⁇ alkoxy include the values of (C,-C 3 )alkoxy, including methoxy, ethoxy, propoxy, and isopropoxy.
  • reaction is conducted as known in the art employing a reducing agent such as stannous chloride, zinc chloride, or hydrogen in the presence of (e.g., 10%) palladium-on-carbon catalyst.
  • a reducing agent such as stannous chloride, zinc chloride, or hydrogen
  • the reaction is typically implemented by refluxing in a polar solvent such as a lower alcohol, for example methanol or ethanol.
  • PG is a (conventional) protecting group, preferably a (C,-C 6 )acyl (for example, acetyl), a benzyloxycarbonyl (Cbz) or t-butoxycarbonyl (BOC) group, as known in the art.
  • the reaction can be implemented conventionally by hydrogenation, or with a deprotecting reagent such as an acid (e.g., trifluoroacetic acid or a mineral acid such as HCI) in aqueous/alcoholic solvent medium.
  • an acid e.g., trifluoroacetic acid or a mineral acid such as HCI
  • “Lower” as used herein means (C ⁇ Ca).
  • Protected amine VI can then be deprotected as known in the art to yield amine VII, for example with an inorganic acid or organic acid such as TFA in an inert solvent such as a halogenated hydrocarbon (e.g., chloroform or methylene dichloride), at room temperature for a reaction time typically of about 2 to about 8 hours.
  • an inorganic acid or organic acid such as TFA
  • an inert solvent such as a halogenated hydrocarbon (e.g., chloroform or methylene dichloride)
  • the protecting group PG can be removed by hydrogenolysis using hydrogen in the presence of a palladium-on-carbon catalyst and in an inert solvent such as a lower alcohol or DMF.
  • the hydrogenolysis is typically implemented anywhere from room temperature up to about 90°C.
  • the amine of formula VII can then be treated with an azo-protected epoxide of formula Vlll to yield compound II.
  • This reaction is typically carried out by reacting the amine of formula VII and the epoxide of formula Vlll in a polar aprotic solvent such as dimethyl sulfoxide, dimethyl formamide, acetonitrile or a lower alkanol such as ethanol, isopropanol or butanol, at a temperature from about -10°C to about 125°C.
  • a preferred modification of the above reaction involves pretreatment of the amine of formula VII with an N-(trialkylsilyl)acetamide, for example N- (trimethylsilyl)acetamide, to form a silylated compound of the formula Vila
  • silyl group can be removed by standard means such as by mild acid or base hydrolysis. It is noted that a silylated derivative of the formula
  • compound II can be reduced to convert the tetrazole portion of the molecule to the corresponding pyridyl amine by treatment with a suitable reducing agent, as described above in (a).
  • Scheme 2 illustrates the preparation of a compound of formula I using a precursor compound of formula III.
  • An epoxide of formula X wherein W and protecting group PG are as previously defined, can be reacted with amine VII under standard conditions, for example using a polar solvent such as a lower alcohol and implementing the reaction at reflux, typically for a time between 2 and 8 hours.
  • amine Vli is first silylated as described above to make a silylated amine compound of formula Vila above prior to treating it with epoxide X.
  • Scheme 3 illustrates the preparation of a compound of formula XVI which is generic to both intermediates of formulae II and III when Y is O, S, or NH.
  • Amino alcohol IV may first be reacted with compound Va, as described for the reaction of amino alcohol IV with compound V for Scheme 1. If X and Y are the same, then the YH moiety need not be protected by pre-reacting with a blocking reagent. If X and Y are different, however, then protecting the YH moiety by standard means, for example by pre-reacting it with an aromatic or aliphatic carboxylic acid, is preferred. De- protection by standard means (e.g.
  • Scheme 4 illustrates the preparation, via reductive amination, of compound XVIa, a subset of formula XVI wherein at least one of R 4 and R 5 is H and the other of R 4 and R 5 is H or (C ⁇ C ⁇ alkyl.
  • Amine XVII and ketone (or aldehyde if R 4 is H) XVIII are reacted to produce a compound of formula XVIa.
  • This reaction is typically carried out in the presence of a reducing agent such as sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, hydrogen and a metal catalyst, zinc and hydrochloric acid, or borane dimethyl sulfide followed by treatment with formic acid.
  • reaction inert solvents for this reaction include lower alcohols (e.g., methanol, ethanol and isopropanol), acetic acid, chlorinated hydrocarbon solvents (e.g., methylene chloride, chloroform, 1,2 dichloroethane) and THF.
  • the solvent is 1,2- dichloroethane
  • the temperature is about 25°C
  • the reducing agent is sodium triacetoxyborohydride.
  • Scheme 6 refers to the preparation of compounds of formulae VII wherein at least one of R 4 and R s is H, and XVIII wherein X is O or S.
  • Compounds of formula VII wherein at least one of R 4 and R s is H are labeled as VIIc in Scheme 6.
  • R 4 is illustrated as the variable which can assume values other than H, although it is to be understood that R 5 can be the variable as well.
  • Compounds of formulae VIIc and XVIII are starting materials for the synthesis, respectively, of intermediates of formulae II and III in Schemes 1 and 2, and of formula XVIa in Scheme 4, which intermediates can in turn be used to make compounds of formula I.
  • compounds of formula Vile are made by reductive amination of a compound of formula XVIII.
  • the conditions for reductive amination are as described above for the conversion of a ketone (or aldehyde, as appropriate) of formula XVIII to a compound of formula XVIa in Scheme 4, with the exception that the amine used is ammonia or an acid addition salt thereof, instead of the amine of formula XVII.
  • Compounds of formula XVIII can be made in three steps beginning with compounds of the formula XX.
  • Suitable solvents for the aforesaid reaction are non-polar aprotic solvents such as methylene chloride, toluene, chloroform, or carbon tetrachloride.
  • the solvent is methylene chloride.
  • the temperature of the reaction may range from about -78°C to about 20°C during the reaction with boron tribromide. It is preferably about O°C.
  • J is chloro, bromo or iodo, in the presence of a base.
  • the thiol or phenol of formula XXI is first converted into an anion by reaction with a base.
  • bases include sodium hydride and potassium t-butoxide.
  • the preferred base is sodium hydride (NaH).
  • suitable solvents for the aforesaid process include polar aprotic solvents such as dimethyl formamide, dimethylsulfoxide, and sulfolane.
  • the solvent is dimethyl formamide.
  • the temperature for the aforesaid reaction is in the range of about -10°C to about 100°C. Preferably, the temperature is 30°C.
  • the ketal or acetal of formula XXII so formed is converted into the corresponding compound of formula XVIII by reaction with an acid.
  • this reaction is conducted at a temperature in the range of about 10°C to about 100°C.
  • appropriate acids for the aforesaid process are hydrochloric, hydrobromic and sulfuric acids.
  • the acid is hydrochloric acid.
  • Suitable solvents for the aforesaid process include polar solvents such as acetone and/or water.
  • the solvent is acetone.
  • Scheme 7 refers to the preparation of compounds of the formulae VIIc and XVIII wherein X is a direct link and at least one of R 4 and R s is H, with the remaining member of R 4 and R 5 being H or Again, the single variable value R 4 is shown for pu oses of illustration.
  • Compounds of the formulae VIIc and XVIII are starting materials for the synthesis of corresponding intermediates useful in the invention as illustrated in Schemes 1 , 2 and 4.
  • a compound of formula XVIII can be converted into a compound of formula VIIc by reductive amination of a compound of the formula XVIII with ammonia as described above for Scheme 6.
  • a compound of formula XVIII can be prepared from a corresponding compound of formula XXIII, by treatment of a compound of the formula XXIII with a tin reagent of the formula R 4 COCH 2 Sn(CH 3 CH 2 CH 2 CH 3 ) 3 in the presence of palladium (II) acetate and tri-o-tolylphosphine.
  • the tin reagent, R 4 COCH 2 Sn(CH 3 CH 2 CH 2 CH 3 ) 3 is formed by reaction of tributyltin methoxide with a compound of the formula
  • Suitable solvents for the aforesaid process include nonpolar solvents such as toluene, benzene and hexane.
  • the solvent is toluene.
  • the temperature for the aforesaid process is generally in the range of about 10°C to about 150°C, and is preferably about 95°C.
  • Scheme 8 illustrates the preparation of an epoxide of formula Vlll, which is used to make an intermediate of formula II and, in turn, a compound of formula I wherein W is CH.
  • the preparation is generally according to methods disclosed in U. S. patents 4,358,455 and 5,019,578.
  • a ketone of formula XXIV can be treated with sodium azide in the presence of an acid such as any of the common mineral acids (e.g., HCI) at reflux in a protic solvent such as aqueous alcohol to yield a tetrazole of formula XXV.
  • Tetrazole XXV can then be treated, preferably with a halogenating agent such as bromine, to yield a corresponding compound of formula XXVI wherein J is a leaving group such as a bromo group.
  • Bromination can be carried out under standard conditions, for example in glacial acetic acid solvent which has been saturated with HBr. Generally the reaction is conducted under chilled (e.g, ice bath) conditions.
  • the compound of formula XXVI can then be converted to the corresponding oxirane Vlll under standard conditions, for example by treating compound XXVI with a mild reducing agent (e.g., sodium borohydride, lithium borohydride) at room temperature in an inert solvent such as THF, followed by treatment with a base such as an alkali metal hydroxide in a protic solvent such as an alcohol.
  • a mild reducing agent e.g., sodium borohydride, lithium borohydride
  • THF inert solvent
  • a base such as an alkali metal hydroxide
  • a protic solvent such as an alcohol.
  • a stereospecific reducing agent such as (R)-alpine borane, may be used to prepare the R-isomer of the oxirane, substantially free of the S-isomer.
  • Scheme 9 illustrates the synthesis of compounds of formula I when R 1 and/or R 2 are other than H.
  • a ketone of formula XXVII wherein L is a group such as F or Cl which can be displaced by a primary or secondary amine, is first treated with a halogenating agent such as bromine to yield a corresponding compound of formula XXVIII wherein J is a leaving group such as a bromo group.
  • Bromination can be effected under standard conditions, for example as described in Scheme 8 for the conversion of tetrazole XXV to compound XXVI.
  • the compound of formula XXVIII can then be converted to the corresponding oxirane XXIX, by the standard procedure also described in Scheme 8.
  • Oxirane XXIX can then be reacted directly with a compound of formula VII, in a polar solvent such as DMSO, DMF, or acetonitrile, at a temperature typically in the range of -10°C to 125°C, thereby yielding a compound of formula XXX.
  • the intermediate of formula XXX can be reacted in a lower alcohol, at reflux (or under pressure, for example if the amine is gaseous), with an amine of formula HNR 1 R 2 to produce a corresponding compound of formula I.
  • Certain of the compounds of formula I form pharmaceutically-acceptable cation salts by reacting the free acid forms with an appropriate base, usually one equivalent, in a co-solvent.
  • bases are sodium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, potassium methoxide, magnesium hydroxide, calcium hydroxide, benzathine, choline, diethanolamine, piperazine and tromethamine.
  • the salt is isolated by concentration to dryness or by addition of a non-solvent.
  • salts are preferably prepared by mixing a solution of the acid with a solution of a different salt of the cation (sodium or potassium ethylhexanoate, magnesium oleate), employing a solvent (e.g., ethyl acetate) from which the desired cationic salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.
  • a solvent e.g., ethyl acetate
  • the acid addition salts of the compounds of the present invention are readily prepared by reacting the base forms with the appropriate acid.
  • the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate)
  • the hydrogen form of a dibasic acid e.g., the hydrogen sulfate, the succinate
  • the dihydrogen form of atribasic acid e.g., the dihydrogen phosphate, the citrate
  • at least one molar equivalent and usually a molar excess of the acid is employed.
  • the amino acid prodrugs of this invention may be prepared by conventional peptide coupling reactions coupling a free amino or carboxylic group of the compound of formula I with an amino acid or a polypeptide, e.g. dipeptide, chain.
  • the coupling reaction is generally conducted at a temperature of about -30° to about 80° C, preferably about 0° to about 25°C.
  • Suitable coupling reagents are usually present, such as dicyclohexylcarbodiimide with hydroxybenzotriazole (HBT), N-3- dimethylaminopropyl-N'-ethylcarbodiimide with HBT, 2-ethoxy-1-ethoxycarbonyl-1,2- dihydroquinoiine, carbonyl diimidazole with HBT, or diethylphosphoryl-cyanide.
  • HBT hydroxybenzotriazole
  • the reaction is generaly conducted in an inert solvent such as aceton ' itrile, methylene chloride, chloroform, dimethylformamide, dioxane, tetrahydrofuran, dimethoxyethane, or water, or a mixture of two or more such solvents.
  • Ester, carbonate or carbamate prodrugs of this invention may be prepared by reaction of a free hydroxyl or amino group of the compound of formula I with an activated carbonyl containing molecule such as acetyl chloride or ethyl chloroformate.
  • the reaction can be carried out neat or in the presence of a reaction inert solvent such as methylene chloride, at a temperature from about -78° to about 100°C.
  • Alcohols can also be reacted with cyanogen chloride in the presence of a Lewis acid to form carbamates.
  • the dosage is in the range of about 0.01 to about 20 mg/kg body weight of the subject per day, preferably about 0.1 to about 10 mg/kg body weight per day, administered singly or as a divided dose.
  • the optimum dosage for the individual subject being treated will be determined by the person responsible for the treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage. This will vary according to the particular compound employed and with the subject being treated.
  • the compounds of the present invention are used in combination with a pharmaceutically acceptable carrier or diluent.
  • suitable pharmaceutically-acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
  • carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
  • the active compound will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described above.
  • the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
  • the pharmaceutical compositions may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like.
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, com starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as com starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • active compounds may also be administered parenterally.
  • parenteral administration the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
  • Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersions can also be prepared in sesame or peanut oil, ethanol, water, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, vegetable oils, N-methyl glucamine, polyvinylpyrrolidone and mixtures thereof in oils as well as aqueous solutions of water-soluble pharmaceutically acceptable salts of the compounds.
  • injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being the preferred parenteral route in man.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the effective dosage of the active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated.
  • the compounds of the present invention possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in edible animals including poultry and ungulate animals such as swine, cattle, sheep, and goats.
  • Compounds of formula I can additionally be used for the treatment of obese household pets, for example companion animals such as dogs and cats.
  • the administration of a compound of formula I can be effected orally or non-orally, for example by injection.
  • An amount of a compound of formula I is administered such that an effective dose is received, generally a daily dose which, when administered orally to an animal is usually between 0.01 and 20 mg/kg of body weight, preferably between 0.05 and 10 mg/kg of body weight.
  • the medication can be carried in the drinking water so that a therapeutic dosage of the agent is ingested with the daily water supply.
  • the agent can be directly metered into drinking water, preferably in the form of a liquid, water-soluble concentrate (such as an aqueous solution of a water soluble salt).
  • the active ingredient can also be added directly to the feed, as such, or in the form of an animal feed supplement, also referred to as a premix or concentrate.
  • a premix or concentrate of therapeutic agent in a carrier is more commonly employed for the inclusion of the agent in the feed.
  • Suitable carriers are liquid or solid, as desired, such as water, various meals such as alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, corncob meal and com meal, molasses, urea, bone meal, and mineral mixes such as are commonly employed in poultry feeds.
  • a particularly effective carrier is the respective animal feed itself; that is, a small portion of such feed. The carrier facilitates uniform distribution of the active materials in the finished feed with which the premix is blended.
  • the agent may be dispersed or dissolved in a suitable oily vehicle such as soybean oil, com oil, cottonseed oil, and the like, or in a volatile organic solvent and then blended with the carrier.
  • a suitable oily vehicle such as soybean oil, com oil, cottonseed oil, and the like
  • the proportions of active material in the concentrate are capable of wide variation since the amount of agent in the finished feed may be adjusted by blending the appropriate proportion of premix with the feed to obtain a desired level of therapeutic agent.
  • High potency concentrates may be blended by the feed manufacturer with proteinaceous carrier such as soybean oil meal and other meals, as described above, to produce concentrated supplements which are suitable for direct feeding to animals. In such instances, the animals are permitted to consume the usual diet. Alternatively, such concentrated supplements may be added directly to the feed to produce a nutritionally balanced, finished feed containing a therapeutically effective level of a compound according to the invention.
  • the mixtures are thoroughly blended by standard procedures, such as in a twin shell blender, to ensure homogeneity.
  • the supplement is used as a top dressing for the feed, it likewise helps to ensure uniformity of distribution of the active material across the top of the dressed feed.
  • Drinking water and feed effective for increasing lean meat deposition and for improving lean meat to fat ratio are generally prepared by mixing a compound of the invention with a sufficient amount of animal feed to provide from about 10 "3 to 500 ppm of the compound in the feed or water.
  • the preferred medicated swine, cattle, sheep and goat feed generally contain from 1 to 400 grams of active ingredient per ton of feed, the optimum amount for these animals usually being about 50 to 300 grams per ton of feed.
  • the preferred poultry and domestic pet feeds usually contain about 1 to 400 grams and preferably 10 to 400 grams of active ingredient per ton of feed.
  • the compounds of the present invention may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal in which increase in lean meat deposition and improvement in lean mean to fat ratio is sought.
  • parenteral administration involves injection of a sufficient amount of the compounds of the present invention to provide the animal with 0.01 to 20 mg/kg/day of body weight of the active ingredient.
  • the preferred dosage for poultry, swine, cattle, sheep, goats and domestic pets is in the range of from 0.05 to 10 mg/kg/day of body weight of active ingredient.
  • Paste formulations can be prepared by dispersing the active compound in a pharmaceutically acceptable oil such as peanut oil, sesame oil, com oil or the like.
  • Pellets containing an effective amount of a compound of the present invention can be prepared by admixing a compound of the present invention with a diluent such as carbowax, carnuba wax, and the like, and a lubricant, such as magnesium or calcium stearate, can be added to improve the pelleting process.
  • the present invention has several advantagous veterinary features.
  • the present invention provides the means by which this can be accomplished.
  • using the method of the present invention yields leaner animals which command higher prices from the meat industry.
  • the compounds of this invention may be tested for hypoglycemic activity according to the following procedure.
  • mice Five to eight week old C57 BL 6J-ob/ob mice (obtained from Jackson Laboratory, Bar Harbor, Maine) are housed five per cage under standard animal care practices. After a one week acclimation period, the animals are weighed and 25 microliters of blood is collected via an ocular bleed prior to any treatment. The blood sample is immediately diluted 1 :5 with saline containing 2% sodium heparin, and held on ice for glucose analysis.
  • Animals are then regrouped, in groups of five per cage, such that the mean glucose values of the groups are similar, dosed daily for five days with test drug (0.01-20 mg/kg), a positive control such as englitazone or ciglitazone (50mg/kg p.o.), (U.S. Patent 4,467,902; Sohda et al.. Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984)), or vehicle. All drugs are administered by oral gavage in a vehicle consisting of 0.25% w/v methyl cellulose. On day 5, the animals are weighed again and bled (via the ocular route) for blood glucose levels.
  • the freshly collected samples are centrifuged for two minutes at 10,000 xg at room temperature.
  • the supernatant is analyzed for glucose, for example, by the ABA 200 Bichromatic AnalyzerTM 1 , using the A-gentTM glucose UV reagent system 2 (hexokinase method) using 20, 60 and 100 mg/dl standards.
  • Plasma glucose is then calculated by the equation,
  • the animals dosed with vehicle maintain substantially unchanged hypergiycemic glucose levels (e.g., 250 mg/dl), while positive control animals have depressed glucose levels (e.g., 130 mg/dl).
  • the glucose lowering activity of test compounds is expressed in terms of % glucose normalization. For example, a glucose level which is the same as the positive control is expressed as 100%.
  • Selectivity of a compound for ⁇ 3 -receptors over ⁇ 2 and ⁇ 1 receptors may be determined using the following procedures.
  • In vitro selectivity may be determined by measurement of cyclic adenosine mono-phosphate (cAMP) accumulation in Chinese hamster ovary cells.
  • cAMP cyclic adenosine mono-phosphate
  • In vivo efficacy may be determined by measurement of oxygen consumption and ambulatory activity on male Sprague-Dawley rats.
  • Whole animal oxygen consumption may be measured using an open circuit, indirect calorimeter (OxymaxTM, from Columbus Instruments).
  • the Oxymax gas sensors are calibrated with nitrogen (N 2 ) gas and gas mixture (0.5% carbon dioxide (CO 2 ), 20.5% oxygen (O 2 ), 79% N 2 ; Linde Specialty gases) before each experiment.
  • Rats male, Sprague Dawley, 300-380 g body weight
  • the Oxymax calorimeter software calculates the oxygen consumption (ml/kg/h) based on the flow rate of air through the chambers and difference in oxygen content at inlet and output ports.
  • the activity monitors have 15 infrared light beams spaced one inch apart on each axis; ambulatory activity is recorded when two consecutive beams are broken (repeated interruptions of the same beam are not registered) and the results are recorded as counts. Basal oxygen consumption and ambulatory activity can be measured every 10 minutes for 2.5 to 3 hours. At the end of the basal period, the chambers are opened and the test compound (0.01 to 20 mg/kg, prepared in water or other suitable vehicle) or an equivalent volume of vehicle is administered by oral gavage.
  • Oxygen consumption and ambulatory activity can be measured every 10 minutes for an additional three hours post-dosing. Percent change in oxygen consumption may be calculated by averaging the post-dosing values for 2.5 hours and dividing by basal oxygen consumption (average of the predosing values except the first hour). Oxygen consumption values obtained during time periods where ambulatory activity exceeds 100 counts are excluded from the calculation. Thus, the values represent % change in resting oxygen consumption.
  • in vivo selectivity for ⁇ , and ⁇ 2 adrenergic receptors may be determined by measurements of heart rate, blood pressure and plasma potassium concentration gathered on conscious catheterized rats (male, Sprague Dawley, 300-380 g body weight).
  • rats are anesthetized with pentobarbital (50-60 mg/kg, i.p.) and the left carotid artery is cannulated with PE50 tubing.
  • the catheter is tunneled subcutaneously, exteriorized at the back of the neck, filled with a solution of polyvinylpyrrolidone in heparinized saline, flame-sealed and taped.
  • Experiments are performed 7 days after surgery. On the day of the experiment, the catheters are untaped and flushed with saline.
  • basal values for heart rate and blood pressure are measured by attaching the catheter to a pressure transducer, the results recorded on a Grass Model 7 polygraph, and a basal blood sample (0.5 ml) is obtained from the arterial catheter.
  • the test compound or vehicle is administered by oral gavage, and blood pressure (measure of ⁇ 2 activity) and heart rate (measure of ⁇ , activity) measurements are taken at 15, 30, 45 and 60 minutes and blood samples for potassium determination ( ⁇ 2 ) are obtained at 30 and 60 min.
  • Isoproternol, a non-selective ⁇ -agonist can be tested as a positive control at doses ranging from 0.001 to 1 mg/kg (injected s.c. in saline vehicle). Plasma potassium is determined by flame spectrophotometry. To determine changes, basal values are subtracted from the average of the post dosing values.
  • Compounds of the formula I also have the effect of reducing intestinal motility and thus find utility as aiding in the treatment of various gastrointestinal disorders such as irritable bowel syndrome, peptic uiceration, esophagitis, gastritis and duodenitis, (including that induced bvH. pylori), intestinal ulcerations (including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis) and gastrointestinal ulcerations. It has been proposed that the motility of non-sphincteric smooth muscle contraction is mediated by activity at ⁇ 3 adrenergic receptors.
  • jn vivo activity of the compounds of formula I for the treatment or prevention of intestinal motility disorders can be determined according to the following procedures. Eighteen-hour fasted male Sprague Dawley derived (CD) rats (175-225 grams) are dosed with 0.01 - 20 mg/kg p.o. of compound or vehicle (distilled water). Thirty minutes after drug administration, the rats are orally dosed with 0.25 ml of a solution of sodium chromate in 0.9% saline containing about 20,000 cpm of 5 Cr (specific activity 350 mCi/mg Cr).
  • the rats are sacrificed, the gastroesophageal, pyloric, and ileocecal junctions are then iigated, and the stomachs and small intestines removed.
  • the small intestines are then divided into ten equal lengths, and the stomach and each length of intestine assayed for radioactivity with a gamma counter. Gastric emptying rate may then be determined for each rat by comparing the amount of radioactivity in the intestine relative to the total in the intestine plus stomach.
  • the geometric center of the distribution of the radioactive marker is then used as a measure of the overall transit rate through the stomach and intestine.
  • geometric center ⁇ ((fraction of 51 Cr per segment) x (segment number)).
  • the stomach may be considered segment number 0, and the ten intestinal segments as numbers 1 to 10.
  • a geometric center of 0.0 would indicate that the entire load of 51 Cr had remained in the stomach.
  • Data from two experiments may be pooled, and statistical evaluations can be made using Dunnetfs multiple comparison test.
  • groups of 8 overnight-fasted male Sprague-Dawley (CD) rats
  • In vitro activity for relaxation of contracted ileum from isolated guinea pig ileum can be determined according to the following procedure. Fresh isolated segments of guinea pig ileum (about 1.5 cm long) are mounted in tissue baths containing Tyrode's physiological salt solution at 30°C and aerated continuously with O 2 :CO 2 (95%:5%). Tissues are then equilibrated for 60-90 minutes under 4.0 gm tension in order to achieve stable baselines. Histamine is then added to the baths in a cumulative fashion in concentrations ranging from 1 nM to 10 ⁇ M. The maximum tension generated after each addition of histamine is recorded on a Grass Physiograph.
  • the tissues are then washed with several changes of Tyrode's solution, basal tension can be readjusted to 4.0 grams, and a stable baseline is then again obtained.
  • Each tissue may then be exposed to a single concentration of test compound (range 1 nM to 10 M) or vehicle and after a 30 minute equilibration period, the histamine does response curve may then be repeated. Results from multiple experiments are standardized (0-100%) to the maximum response of the control tissues and plotted as percent maximum tension versus the log of the histamine concentration in the absence and presence of the drug.
  • Compounds of formula I can be assessed for antidepressant activity in vivo according to the following procedure.
  • mice Male CD1 mice weighing between 20 and 25 g, and Sprague-Dawley rats weighing between 200 and 250 g, may be obtained from Charles River, USA. Compounds of formula I are dissolved in water. The compounds may be administered to mice in a volume of 10 ml kg '1 , and to rats in a volume 2 ml kg '1 . Control animals receive the vehicle. Positive test results for the following parameters indicate antidepressant activity.
  • mice are given reserpine (2.5 mg kg '1 i.p. dissolved in 1% citric acid). Their rectal temperatures may be measured 3.5 h later. The mice may then be divided into different groups so as to obtain the same mean rectal temperature in each group. Half an hour later (i.e. 4 h after reserpine), the mice are given the vehicle or test drug. Rectal temperature can be measured again 90 min later (i.e. 5 h 30 min after the injection of reserpine) (Bourin et aL, The Value of the Reserpine Test in Psvchopharmacology. Arzneim. Forsch. 33, 1173, (1983)).
  • mice Half an hour after the mice are placed in individual cages, their rectal temperatures are recorded. The animals should be allocated so as to obtain the same mean rectal temperature in each group.
  • Apomorphine (16 mg kg '1 s.c.) can be given 30 min after the test drug or its vehicle. Rectal temperature can be measured again 30 min after the apomorphine treatment (Puech et al, Antagonism of Hypothermia And Behavioural Response To Apomorphine: A Simple. Rapid And Discriminating Test For Screening Antidepressants And Neuroleptics. Psvchopharmacology 75, 84, (1981)).
  • Avoidance training is initiated 48 h (day 3) after inescapable shock in automated two- way shuttle-boxes (60 X 21 X 30 cm) with Plexiglass* walls and a floor consisting of stainless-steel rods spaced 1.0 cm apart in order to evaluate escape deficits.
  • Each shuttle-box is divided into two chambers of equal size by a stainless-steel partition, with a gate providing access to the adjacent compartment through a 7 X 7 cm space.
  • Shuttle-box sessions are performed for 3 consecutive days (days 3, 4 and 5). The animals are placed individually in the shuttle-box and allowed to habituate to the environment for 5 min (for the first session only) and then subjected to 30 trials.
  • the intertrial interval should be 30 s.
  • a light signal, used as a conditioned stimulus, is presented during the first 3 s of each trial. Crossing the gate into the other compartment of the box during this 'conditioned-stimulus only 1 period (referred to as avoidance response) allows the rats to avoid shocks. A period with conditioned stimulus plus electric foot-shock (0.8 mA) may be presented if an avoidance response does not occur. Crossing the gate into the other compartment during this conditioned stimulus plus shock period is referred to as an escape response. Absence of escape response during the 3-s duration conditioned stimulus plus shock should be considered to be an escape failure.
  • Compounds of formula I also have the effect of bronchial relaxation and increased ciliary motility and thus may be useful in the treatment of airway inflamatory disorders such as asthma and obstructive lung disease.
  • In vitro activity of compounds for the treatment of airway inflamatory disorders can be determined by measurement of guinea-pig bronchial ring relaxation according to the following procedure.
  • Guinea-pig main bronchial rings are obtained from tricolored guinea-pigs of either sex (250-350g) anesthetized with urethane (1.25 g kg '1 , i.p.) and are suspended under an initial tension of 2.0 g in Krebs solution at 37° C gassed with 95% O 2 :5% CO 2 . After 1 h of equilibration, guinea-pig bronchial rings are contracted with acetylcholine (10 "3 M) and relaxed to maximal relaxation with theophylline (3 x 10 "3 M), then allowed to equilibrate for a further 60 min while they are washed with Krebs solution every 15 min.
  • the composition of the Krebs solution is (mM): NaCI 118.0, KCI 5.4, CaCI 2 2.5, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 25.0 and glucose 11.7.
  • in vitro activity of the compounds of formula I for prostate disease can be determined according to the following procedures. Ventral prostates of male Sprague-Dawley rats (300-400g) anesthetized with diethylether are quickly excised and placed in oxygenated Krebs solution. While maintained at room temperature in this buffer, adherent fatty and connective tissues are removed.
  • the prostates are then suspended in 10-ml organ baths containing Krebs solution warmed to 37° C and aerated with a mixture of 95% O 2 and 5% CO 2 .
  • the composition of the Krebs solution is 118.4 mM NaCI, 4.7 mM KCI, 1.2 mM MgSO 4 , 2.5 mM CaCI 2 , 11.1 mM dextrose, 25.0 mM NaHCO 3 and 1.2 mM KH 2 PO 4 , dissolved in distilled and demineralized water.
  • the tissues are attached to isometric force- displacement transducers and isometric contraction is recorded under a loading tension of 0.5g. Equilibration is undertaken for 1 or 2 hr before the addition of test compounds.
  • Submaximal contractions are first elicited by repeated concentrations of 1 x 10*M phenylephrine until constant responses are obtained.
  • the control and test compound-treated experiments are done in different preparations.
  • a concentration- response curve to cumulate concentrations of phenylephrine or acetylcholine (10 *9 to lO ⁇ M) is determined.
  • a concentration response curve to phenylephrine or acetylcholine is determined in the presence of the ⁇ agonists.
  • in vitro activity of test compounds can also be determined for specific efficacy in human prostate as follows. Prostatic tissue specimens are obtained from patients with symptomatic BPH, who are undergoing open prostatectomy.
  • Isolated human prostatic tissue is cut into five to eight strips (3mm wide, 3mm thick and 15mm long in each strip).
  • the strips are mounted vertically in organ baths containing 20 ml Krebs-Henseleit solution of the following composition (mM): NaCI 112, KCI 5.9, MgCI 2 1.2, CaCI 2 2, NaHCO 3 25, NaHPO 4 1.2, glucose 11.5.
  • the medium is maintained at 37°C and at pH 7.4, and is equilibrated with a gas mixture consisting of 95% O 2 and 5% CO 2 .
  • a resting tension of 0.5g is applied and the responses are recorded isometrically through a force- displacement transducer.
  • the preparations are equilibrated for 90 min before starting the experiments.
  • Concentration-response curves for phenylephrine or acetylcholine (10 '9 to 10 " *M) are determined by adding the drug directly to the bathing media in a cumulative fashion.
  • the prostate strips are incubated in the presence of compound (1 or 10 /M) for 30 minutes before and then phenylephrine or acetylcholine are added to the medium in a cumulative fashion to obtain to the concentration-response curve in the presence of the test compound.
  • Compounds of the formula I lower trigiyceride levels and cholesterol levels and raise high density lipoprotein levels and are therefore of use in combating medical conditions wherein such lowering (and raising) is thought to be beneficial. Thus they may be used in the treatment of hypertriglyceridaemia, hypercholesterolemia and conditions of low HDL (high density lipoprotein) levels in addition to the treatment of atherosclerotic disease such as of coronary, cerebrovascular and peripheral arteries, cardiovascular disease and related conditions.
  • the active compounds may also be combined with other active ingredients known for use in the treatment of atherosclerosis and related conditions, for example fibrates such as clofibrate, bezafibrate and gemfibrozil; inhibitors of cholesterol biosynthesis such as HMG-CoA reductase inhibitors for example lovastatin, simvastatin and pravastatin; inhibitors of cholesterol absorption for example beta-sitosterol and (acyi CoA; cholesterol acyltransferase) inhibitors for example melinamide; anion exchange resins for example cholestyramine, coiestipol or a dialkylaminoalkyl derivatives of a cross-linked dextran; nicotinyl alcohol, nicotinic acid or a salt thereof; vitamin E; and thyromimetics.
  • fibrates such as clofibrate, bezafibrate and gemfibrozil
  • inhibitors of cholesterol biosynthesis such as HMG-CoA reductase inhibitors for example
  • VP Super System Autoanalyzer Abbott, Irving, TX
  • Activity of compounds of formula I for decrease in body fat can be determined according to the following procedure.
  • C57BL6J ob/ob mice male, 30-40g body weight, Jackson Lab, Bar Harbor, ME are housed 5 mice per cage in an environmentally controlled room with food (pelleted rodent chow) and water available ad libitum.
  • Body weight of each mouse can be measured daily and food intake per cage determined by weighing the amount of food left in the trough.
  • the mice are weighed and then killed by cervical dislocation.
  • the epididymal fat pads from each mouse are excised and weighed.
  • the fat versus body weight ration is determined for each mouse using the absolute body weights and the fat pad weights.
  • a reduction in fat pad weight is indicative of a reduction in total body fat.
  • the present invention is illustrated by the following Examples. However, it should be understood that the invention is not limited to the specific details of these examples.
  • Example 1a Methyl (4-(2-t-butoxycarbonylaminoethoxy)phenyl) acetate
  • methyl 4-hydroxyphenyl acetate (4.00 g, 24.1 mmol) and triphenylphosphine (9.50 g, 36.1 mmol) in THF (24 mL) were added solutions of 2-(t- butoxycarbonylamino)ethanol (5.80 g, 36.1 mmol) and diethylazodicarboxylate (5.70 mL, 36.1 mmol) in THF (6 mL, each) simultaneously over a 1.5 h period.
  • Example 1c Methyl (4-(2-(2(R)-hydroxy-2-tetrazolo[1 ,5-a]pyridin-6-ylethylamino) ethoxy)-phenyl)acetate A solution of methyl (4-(2-aminoethoxy)phenyl) acetate (0.56 g, 2.71 mmol) and
  • Example 2a Following the general methodology of example 1a, methyl 4-(2-t- butoxycarbonylaminoethoxy)benzoate was prepared from 2-(BOC-amino)ethanol and methyl 4-hydroxybenzoate; m.p. 85°C; H NMR (CDCI 3 ) ⁇ 7.90 (d, 2H), 6.82 (d, 2H), 4.92 (br s, 1H), 4.00 (t, 2H), 3.82 (s, 3H), 3.49 (m, 2H), 1.39 (s, 9H).
  • Example 2b Following the general methodology of example 1b, methyl 4-(2- aminoethoxy)benzoate was prepared from the product of Example 2a; m.p. 48°C; 1 H NMR (DMSO-d6) ⁇ 7.84 (d, 2H), 6.97 (d, 2H), 3.94 (t, 2H), 3.77 (s, 3H), 2.84 (t, 2H).
  • Example 2c Following the general methodology of example 1c, methyl (4-(2-(2(R)- hydroxy-2-tetrazolo[1 ,5-a]pyridin-6-ylethylamino)ethoxy)phenyl) benzoate was prepared from the product of Example 2b and (2R)-(tetrazolo[1 ,5-a]pyrid-6-yl)oxirane 1 H NMR (DMSO-d6) ⁇ 9.10 (s, 1H), 8.10 (d, 1 H), 7.90-7.78 (m, 3H), 6.96 (d, 2H), 5.76 (d, 1H), 4.86-4.77 (m, 1 H), 4.04 (t, 2H), 3.78 (s, 3H), 2.91 (t, 2H), 2.83 (d, 2H).
  • Example 2d Following the general methodology of example 1d, methyl 4-(2-(2-(6- aminopyridin-3-yl)-2(R)-hydroxyethyiamino)ethoxy)benzoate was prepared from the product of Example 2c. The product was then combined with 2 equivalents of HCI gas in alcoholic solvent to afford the dihydrochloride salt. m.p.
  • Example 3a Following the general methodology of example 1a, methyl (4-(2-t- butoxycarbonylaminoethoxy)phenyl)propionate was prepared from 2-(BOC- amino)ethanol and 4-hydroxyphenylpropionate, isolated as a colorless oil.
  • 1 H NMR (CDCI 3 ) ⁇ 7.04 (d, 2H), 6.74 (d, 2H), 4.95 (br s, 1H), 3.94 (t, 2H), 3.62 (s, 3H), 3.52-3.40 (m, 2H), 2.84 (t, 2H), 2.54 (t, 2H), 1.40 (s, 9H).
  • Example 3b Following the general methodology of example 1b, methyl (4-(2- aminoethoxy)phenyl)propionate was prepared from the product of Example 3a as a colorless oil. 'H NMR (CDCI 3 ) ⁇ 7.00 (d, 2H), 6.73 (d, 2H), 3.87 (t, 2H), 3.58 (s, 3H), 2.97 (t, 2H), 2.80 (t, 2H), 2.50 (t, 2H).
  • Examole 3c Methyl (4-(2-(2(R)-hydroxy-2-tetrazolo[1 ,5-a]pyridin-6-ylethylamino)- ethoxy)phenyl)propionate
  • Example 3d Following the general methodology of example 1d, methyl (4-(2-(2-(6- aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)propionate was prepared from the product of Example 3c. The product was then combined with 2 equivalents of HCI gas in alcoholic solvent to afford the dihydrochloride salt. m.p. 152-155°C.
  • Example 4a The following derivative, (4-(2-(2(R)-hydroxy-2-tetrazolo[1 ,5-a]pyridin-6- ylethylamino)ethoxy)phenol, was prepared utilizing the above general condition of Example 3c, from 4-(2-aminoethoxy)phenoi and (2R)-(tetrazolo[1 ,5-a]pyrid-6-yl)oxirane. m.p.
  • Example 4b The methyl ester produced as in Example 4b was reduced as described in Example 1 d to produce the title (non-salt) compound.
  • the product was then combined with 2 equivalents of HCI gas in alcoholic solvent to afford the dihydrochloride salt, m.p. 145-148°C.

Abstract

Cette invention concerne des agonistes du récepteur β-adrénergique qu'on utilise pour traiter les maladies/pathologies telles que l'obésité et le diabète. Les composés sont représentés par la formule (I) dans laquelle R?1, R2, R3, R4, R5, R6, R7¿, W, X, Y, et Z sont tels que définis dans le descriptif.
EP95915993A 1995-05-10 1995-05-10 Agonistes du recepteur beta-adrenergique Withdrawn EP0828712A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002220538A CA2220538A1 (fr) 1995-05-10 1995-05-10 Agonistes du recepteur .beta.-adrenergique
PCT/IB1995/000342 WO1996035670A1 (fr) 1995-05-10 1995-05-10 AGONISTES DU RECEPTEUR β-ADRENERGIQUE

Publications (1)

Publication Number Publication Date
EP0828712A1 true EP0828712A1 (fr) 1998-03-18

Family

ID=25679804

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95915993A Withdrawn EP0828712A1 (fr) 1995-05-10 1995-05-10 Agonistes du recepteur beta-adrenergique

Country Status (6)

Country Link
EP (1) EP0828712A1 (fr)
JP (1) JPH11504648A (fr)
CN (1) CN1144801A (fr)
CA (1) CA2220538A1 (fr)
FI (1) FI974170A (fr)
WO (1) WO1996035670A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69735433D1 (de) 1996-11-14 2006-05-04 Pfizer Verfahren zur herstellung von substituierten pyridinen
US6001856A (en) * 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
AU735249B2 (en) * 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
DK1277736T3 (da) 2000-04-28 2007-10-01 Asahi Kasei Pharma Corp Hidtil ukendte bicykliske forbindelser
KR100622461B1 (ko) 2001-10-25 2006-09-19 아사히 가세이 파마 가부시키가이샤 2환식 화합물
KR20060124603A (ko) * 2003-11-03 2006-12-05 베링거 인겔하임 인터내셔날 게엠베하 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
CN102171191A (zh) 2008-10-09 2011-08-31 旭化成制药株式会社 吲唑衍生物
CA2740772A1 (fr) 2008-10-09 2010-04-15 Asahi Kasei Pharma Corporation Compose d'indazole

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
EP0105053B1 (fr) * 1982-10-01 1988-01-20 Merck & Co. Inc. Composés hétérocycliques d'aralkylaminoéthanol
GB8703007D0 (en) * 1987-02-10 1987-03-18 Glaxo Group Ltd Chemical compounds
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5726192A (en) * 1992-12-29 1998-03-10 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
NZ265692A (en) * 1993-06-14 1997-02-24 Pfizer Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9635670A1 *

Also Published As

Publication number Publication date
CN1144801A (zh) 1997-03-12
FI974170A0 (fi) 1997-11-07
JPH11504648A (ja) 1999-04-27
FI974170A (fi) 1997-11-07
WO1996035670A1 (fr) 1996-11-14
CA2220538A1 (fr) 1996-11-14

Similar Documents

Publication Publication Date Title
US5977124A (en) β-adrenergic agonists
US5859044A (en) β-adrenergic agonists
US5843972A (en) Heterocyclic β-adrenergic agonists
US6706743B2 (en) β3 adrenergic receptor agonists and uses thereof
MXPA97008621A (en) Agonistasó-adrenergicos, compositions that contain and use of mis
MXPA97002601A (en) Agonistasó-adrenergicos heterocicli
EP0828712A1 (fr) Agonistes du recepteur beta-adrenergique
US5627200A (en) β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
US6864268B2 (en) β3 adrenergic receptor agonists
US6001856A (en) β-adrenergic agonists to reduce a wasting condition
WO2003072572A1 (fr) Agonistes du recepteur $g(b)3-adrenergique
Cannon et al. 6-Hydroxy-4-[2-di-n-propylaminoethyl] indole: synthesis and dopaminergic actions
US20050075323A1 (en) Beta3 adrenergic receptor agonists and uses thereof
AU4747599A (en) Intermediates for the preparation of beta-adrenergic agonists
US20030199556A1 (en) beta3- adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
MXPA97005815A (es) Agonistasó-adrenergicos
WO2003072571A1 (fr) Sel d'un derive de pyridyle ethanolamine et son utilisation en tant qu'agoniste du recepteur beta-adrenergique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19990701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000112